Advancing Genomic Research
- Furthering investigation that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer
- Leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools
Serving as a Nexus for Collaboration
- Harnessing the combined strengths of our faculty, member institutions, scientific working groups, affiliate members, and industry partners
- For the New York scientific community and beyond
Leading Collaborative Research in Neurodegenerative Disease
Building on the success of NYGC’s global consortium for ALS research to drive discovery for conditions with common disease pathways, including dementia, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and Huntington’s disease.
Expanding Understanding of Neuropsychiatric Disease
Leveraging our large-scale whole genome research of autism patients to related disorders that have commonly implicated genes, such as schizophrenia and bipolar disorder
Focusing on whole genome sequencing of individuals with cancer and their tumors, novel population-level cancer analytics, and the application of both single cell sequencing and spatial transcriptomics
The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. Leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools, the NYGC serves as a nexus for collaboration in genomic research for the New York community and beyond.
NYGC harnesses and builds on the combined strengths of our faculty, member institutions, scientific working groups, affiliate members, and industry partners to advance genomic discovery. Central to our scientific mission is an outstanding faculty who are leading independent research labs based at the NYGC and jointly with one of our member institutions, bringing a multidisciplinary and in-depth approach to the field of genomics.
To learn more about NYGC,
read our A Year in Review 2018.
IN THE NEWS
Hackensack Meridian Health and Georgetown Lombardi Comprehensive Cancer Center Become Associate Members of the New York Genome Center
The new members are joining the NYGC through two separate partnerships with distinct collaborative research objectives focused on cancer genomics and genetics underlying behavioral disorders.
A Conversation with...
NYGC ALS Researcher
Hemali Phatnani, PhD
A forensic pathologist father, their shared love of Perry Mason novels, the study of ALS as a postdoc in the lab of Tom Maniatis, PhD. NYGC’s Hemali Phatnani, PhD, Director, Center for Genomics of Neurodegenerative Disease, shares her journey to becoming a scientist and describes the collaborative work at the NYGC, through the NYGC ALS Consortium, and more with Michael Stoler on CUNY-TV.
Developing New Genomic Tools & Technologies
Genotyping of Transcriptomes (GoT), is a new genomic method that has important implications for investigating cells within genetically heterogeneous populations, such as tumors. GoT was developed in a research collaboration jointly supervised at the New York Genome Center (NYGC) by Core Faculty Member Dan Landau, MD, PhD, who holds a joint appointment at Weill Cornell Medicine, and Peter Smibert, PhD, Senior Manager, NYGC Technology Innovation Lab.
The NYGC Technology Innovation Lab is a dedicated incubator within the NYGC comprised of a multidisciplinary team in which staff scientists and faculty, as well as many research collaborators, can explore and test breakthrough genomic tools and ideas.
Furthering Scientific Inquiry
Our outstanding faculty and staff scientists are recognized as innovators in the field, and in the last five years have published over 200 papers in leading scientific journals helping to advance genomic science. They have received many awards and honors, including three prestigious NIH New Innovator Awards. Their important research has provided new insights, including the discovery of dozens of new genes that create cancer resistance and hundreds of genes that impact the human immune system. NYGC researchers have also contributed to uncovering new genetic signatures for autism, the identification of a novel gene associated with ALS, and a better understanding of the mechanisms and progression of ALS.